In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals are going to be enrolled on the identified monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be supplied as "increase-on" therapy. In https://abbv-744-preclinical-stud46780.blue-blogs.com/39144760/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described